Issue link:

Contents of this Issue


Page 7 of 31

“Cascade impaction” can describe the networking environment at the RDD conferences. The Respiratory Drug Delivery Conferences: Cascade impaction is not just for aerosols anymore The Organizers of the Respiratory Drug Delivery Conference Series RDD Europe provides an oppor- tunity to present your work and capabilities during podium and poster sessions, the technology exhibition or the signature work- shops that allow for a customized delegate meeting experience. See the whole picture at RDD 2020 e RDD conference in the United States is our largest and most comprehensive meeting. e program seeks to combine forward-looking presentations on key topics critical to successful pulmonary and nasal drug admin- istration, including advances in therapeutic approaches, device innovations, basic science and testing methodology, with spirted discussions on regulatory app- roaches such as metrics to estab- lish biological and pharmaceutical equivalence. e audience is par- ticularly diverse, including CEOs and senior scientists from indus- try, influential regulators, and academic experts in clinical, bio- logical, physical and engineering sciences from around the world. e next meeting will be at the JW Marriott Desert Springs Resort & Spa in Palm Desert, California, US and will take place April 26-30, 2020. RDD 2020 will seamlessly merge into the symposium, "e Global Regula- tory Landscape and Advances in Digital Technology: Transforming the OINDP/Patient Experience," organized with the International e topic of "cascade impaction" comes up frequently at Respira- tory Drug Delivery conferences since the technique is extensively used to characterize pulmonary and nasal pharmaceutical aerosols. But the term can reasonably describe the networking environ- ment at the conference series too. RDD ® meetings strategically pro- gram networking opportunities at various points in each conference. Meeting delegates come into con- tact with key opinion leaders, cli- ents and customers, and have numerous chances to determine if their interests align. is cascade of impactful formal and informal meeting opportunities is one of the reasons many delegates attend RDD (in the United States), RDD Europe and RDD Asia. e upcoming RDD conferences will focus on the presentation of qual- ity, timely science and offer the chance to interact with the people and companies who can propel you and your ideas and projects forward so they have maximum impact. On which stage will you present your work? Explore an emerging market with RDD Asia 2018 ere is still time to overcome your inertia and join us at the Grand Hyatt Kochi, Kerala, India, Nov- ember 14-16, 2018. is educa- tional and practically oriented meeting is geared towards intro- ducing Western and Asian scien- tists and companies in order to explore the opportunities that exist for generic and innovator develop- ment of pressurized metered dose and dry powder inhalers along with nasal products. Professor Rob Price, University of Bath, will deliver the plenary lecture, "Chal- lenging the Bioequivalence Hur- dles for OINDPs: Achieving Q3 Structural Equivalence." Generic product development will be an important theme in Kerala, together with the utility of predic- tive models to support product development, as well as insights into the burden of chronic respira- tory disease in India. Hear it first at RDD Europe 2019 RDD Europe 2019 will build on the feedback from the last Euro- pean RDD meeting, yet take place in a new venue—the Estoril Congress Center just outside Lis- bon, Portugal, May 7-10, 2019. With more than 500 delegates representing more than 30 coun- tries expected to congregate in Estoril, and a host of scientific, clinical and regulatory hot-but- ton issues to explore (such as Brexit, connectivity and new therapeutic opportunities and drug design technologies), this meeting is expected to be as provocative as it will be produc- tive. RDD Europe meetings typi- cally introduce new players in the industry while investigators bring novel ideas relevant to pulmonary and nasal drug administration. 6 OctOber 2018 Inhalation organizations Cross-industry

Articles in this issue

view archives of Inhalation - INH1018